Recent News

• 12.02.2025 - Zymeworks Announces Participation in Upcoming Conferences
• 11.24.2025 - Zymeworks Announces Participation in Upcoming Investor Conferences
• 11.18.2025 - Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
• 11.18.2025 - Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
• 11.17.2025 - Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
• 11.06.2025 - Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Recent Filings

• 11.24.2025 - 144 Report of proposed sale of securities
• 11.21.2025 - 144 Report of proposed sale of securities
• 11.19.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 11.18.2025 - EX-99.1 EX-99.1
• 11.18.2025 - 8-K Current report
• 11.17.2025 - EX-99.1 EX-99.1
• 11.17.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.10.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material